Many traumatic brain injuries result in significant communication impairment across a spectrum that can range from limited speaking to apparent disorders of consciousness such as comas.
|Slideshows|September 5, 2019
Psychiatry Roundup: 7 New Developments in Depression
Author(s)Leo Robert
Neurotransmitters may enhance mood-boosting effectS of exercise, cigarette use abstinence efforts going up in smoke, and other recent findings are summarized here.
Advertisement
Advertisement
Related to this article
Review the timeline for Igalmi in at-home treatment of agitation in bipolar disorder and schizophrenia.
Meta-analysis finds bright light therapy boosts remission and response in nonseasonal depression, offering a low-cost add-on to standard care.
Minerva Neurosciences webinar reported that roluperidone monotherapy improved primary negative symptoms and functioning in stable patients with schizophrenia who had a low relapse risk.
Teacher-recorded classroom engagement scores beat GPA at identifying middle schoolers who reported alcohol or cannabis use by eighth grade.
The FDA seems to have shelved the fast-track drug review initiative launched during the Trump administration.
Oveporexton (Orzeyful) is now available in the US by prescription for the treatment of narcolepsy type 1.
Explore the types of scams encountered in psychiatric practice in order to help identify those at risk.
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Shelves Fast-Track Drug Review Initiative
2
Major Depressive Disorder With Mixed Features: Diagnosis and Treatment
3
Oveporexton Now Available: First and Only Orexin Agonist for Narcolepsy Type 1
4
Reviewing Roluperidone as Treatment for Negative Symptoms in Schizophrenia
5